|Day Low/High||84.11 / 85.11|
|52 Wk Low/High||70.89 / 87.35|
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
It becomes difficult for me to tell you where to run in these markets...
There is clear divergence between the best and the worst performers in each sector this earnings season.
Straying from these names could land you in quicksand as the 4th quarter begins.
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
The answer is plenty, but you can't trade that.
Merck is vey overbought on a number of time frames.
Merck shares retreat as regulatory approval ramps up speculation.
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Family offices, which manage billions of dollars and have much fewer restrictions on how they deploy capital, have been wading into the cannabis space with increasing frequency.
These blue chips pay shareholders handsomely in the form of dividends and share buybacks.
The latest announcement from the U.S. Trade Representative's office is chilling reading for free trade supporters.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
Markets have perked up just a tad across the board since our last update. As mentioned in an earlier post, Galmed Pharmaceuticals is the second small-cap NASH (nonalcoholic steatohepatitis) play that has soared over the past week. The shares are up ...
I continue to see these names as bargains in the biotech and biopharma space.
Tech and retail gains aren't enough to lead markets to new highs.
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
These names are moving up or down in a big way ahead of releasing drug-trial results.
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Let's take a look at the charts and indicators to see what may lie ahead for this drug maker.
I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.
Data and industry conferences will likely be catalysts for shares in the space.
Watch for these upstart names to topple some big-caps going forward.